Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain.

Juan Cosín SalesEduard SidelnikovSantiago VillamayorMiriam FernándezSandra Merino-MonteroAlberto Zamora

Published in: Advances in therapy (2022)

Up to 82% of patients with atherosclerotic CV disease do not achieve LDL-C levels recommended by the 2019 ESC/EAS guidelines despite being on optimized oral LLT therapy. In 17.9% of these patients LDL-C levels exceed 100 mg/dL, being eligible for PCSK9i in Spain.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
stem cells
mesenchymal stem cells
cell therapy